

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 6, 2025

Dynabeads™ Human T-Activator CD3/CD28 for T Cell Expansion and Activation

RRID:AB_2916088

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 11161D, RRID:AB_2916088)

Antibody Information

URL: http://antibodyregistry.org/AB_2916088

Proper Citation: (Thermo Fisher Scientific Cat# 11161D, RRID:AB_2916088)

Target Antigen: CD3, CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Magnetic beads covalently coupled to anti-CD3 and anti-CD28 antibodies

Antibody Name: Dynabeads™ Human T-Activator CD3/CD28 for T Cell Expansion and Activation

Description: This monoclonal targets CD3, CD28

Target Organism: human

Antibody ID: AB_2916088

Vendor: Thermo Fisher Scientific

Catalog Number: 11161D

Alternative Catalog Numbers: 11131D, 11132D

Record Creation Time: 20231110T031421+0000

Ratings and Alerts

No rating or validation information has been found for Dynabeads™ Human T-Activator CD3/CD28 for T Cell Expansion and Activation.

No alerts have been found for Dynabeads™ Human T-Activator CD3/CD28 for T Cell Expansion and Activation.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Reilly NA, et al. (2024) Oleic acid triggers metabolic rewiring of T cells poisoning them for T helper 9 differentiation. *iScience*, 27(4), 109496.

Xia Z, et al. (2024) EP300 restores the glycolytic activity and anti-tumor function of CD8+ cytotoxic T cells in nasopharyngeal carcinoma. *iScience*, 27(2), 108957.

Chen D, et al. (2024) A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(17), 3747.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. *Cell*, 187(11), 2690.

Li H, et al. (2023) Exploring the dynamics and influencing factors of CD4 T cell activation using single-cell RNA-seq. *iScience*, 26(9), 107588.

Smith KER, et al. (2023) A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. *Frontiers in immunology*, 14, 1279387.

Kim EH, et al. (2022) Development of an HIV reporter virus that identifies latently infected CD4+ T cells. *Cell reports methods*, 2(6), 100238.

Hu X, et al. (2022) Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2. *EBioMedicine*, 86, 104333.